Back

SGLT2i are Cardiovascular Drugs

31 August 2020 (18:45 - 18:55)
Organised by:
Congress Presentation Part of: Time to Take the Lead – Practical Utilization of SGLT2 Inhibitors Pharmacotherapy Open Access ESC Congress 2020

About the speaker

Photo
Professor Javed Butler

Baylor Scott & White Health, Dallas (United States of America)

4 More presentations in this session

Presentation thumbnail
Session Introduction.
Professor J. Butler (Dallas, US)
Video
Presentation thumbnail
No Permission Needed.
Doctor S. Zieroth (Winnipeg, CA)
Video
Presentation thumbnail
Cardiologist Taking the Lead – Practical Initiation and Management
Professor S. Anker (Berlin, DE)
Video
Presentation thumbnail
Live panel discussion and close.
Doctor S. Zieroth (Winnipeg, CA) Professor S. Anker (Berlin, DE) Professor J. Butler (Dallas, US)
Video

Access the full session

Session thumbnail
Time to Take the Lead – Practical Utilization of SGLT2 Inhibitors
Video

The Event

Event poster

ESC Congress 2020

31 August 2020 18:45 CET
You may be interested in
thumbnail
Congress Presentation
Cardiovascular benefits of SGLT2i in type 2 diabetes without heart failure: a subgroup analysis
30 August 2025
thumbnail
Congress Session
Novel therapies in managing patients with cardiovascular-kidney-metabolic (CKM) syndrome and heart failure
4 April 2025
thumbnail
Webinar
Early initiation of SGLT-2 inhibitors after acute decompensated heart failure
26 October 2022
thumbnail
Congress Presentation
Cardiovascular protection by combination of the selective nonsteroidal MR antagonist finerenone and the SGLT2 inhibitor empagliflozin in a preclinical model of hypertension-induced end-organ damage
27 August 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources